title: Pharmacology for common urologic diseases: 2011 review for the primary care physician.
abstract: Coordination of care between the urologist and primary care physician is critical to effective treatment of a variety of urologic conditions. Medical therapies for benign prostatic hyperplasia, erectile dysfunction, hypogonadism, overactive bladder, and prostate cancer are widely available and a basic understanding of the pathophysiology of these disease states as well as the pharmacology of existing treatment options are necessary to avoid complications and maximize efficacy associated with patient outcomes. Important regulatory decisions have been made concerning the approval and lack of approval of several important urologic medications. Major advances have been made in the therapy of castrate resistant prostate cancer as well as hormonal related skeletal events secondary to advanced carcinoma of the prostate. We provide a 2011 update of the available medications for treatment of several common urologic diseases.
authors.affiliation: Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
authors.forename: Xiaolong S
authors.initials: XS
authors.lastname: Liu
authors.forename: Christine
authors.initials: C
authors.lastname: Folia
authors.forename: Leonard G
authors.initials: LG
authors.lastname: Gomella
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007006:Hypogonadism / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy; D014570:Urologic Diseases / Q000188:drug therapy*
chemical_list: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists